95 related articles for article (PubMed ID: 21078722)
1. Medication use in systemic lupus erythematosus.
Bernatsky S; Peschken C; Fortin PR; Pineau CA; Urowitz MB; Gladman DD; Pope JE; Hudson M; Zummer M; Smith CD; Arbillaga HO; Clarke AE;
J Rheumatol; 2011 Feb; 38(2):271-4. PubMed ID: 21078722
[TBL] [Abstract][Full Text] [Related]
2. The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study.
Bernatsky S; Joseph L; Boivin JF; Gordon C; Urowitz M; Gladman D; Fortin PR; Ginzler E; Bae SC; Barr S; Edworthy S; Isenberg D; Rahman A; Petri M; Alarcón GS; Aranow C; Dooley MA; Rajan R; Sénécal JL; Zummer M; Manzi S; Ramsey-Goldman R; Clarke AE
Ann Rheum Dis; 2008 Jan; 67(1):74-9. PubMed ID: 17545189
[TBL] [Abstract][Full Text] [Related]
3. The 1000 Canadian faces of lupus: determinants of disease outcome in a large multiethnic cohort.
Peschken CA; Katz SJ; Silverman E; Pope JE; Fortin PR; Pineau C; Smith CD; Arbillaga HO; Gladman DD; Urowitz M; Zummer M; Clarke A; Bernatsky S; Hudson M;
J Rheumatol; 2009 Jun; 36(6):1200-8. PubMed ID: 19369456
[TBL] [Abstract][Full Text] [Related]
4. The impact of disease activity, treatment and disease severity on short-term costs of systemic lupus erythematosus.
Lacaille D; Clarke AE; Bloch DA; Danoff D; Esdaile JM
J Rheumatol; 1994 Mar; 21(3):448-53. PubMed ID: 8006887
[TBL] [Abstract][Full Text] [Related]
5. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance.
Hanly JG; McCurdy G; Fougere L; Douglas JA; Thompson K
J Rheumatol; 2004 Nov; 31(11):2156-62. PubMed ID: 15517627
[TBL] [Abstract][Full Text] [Related]
6. Treatment pathways in an inception lupus cohort over the first three years.
Hanly JG; Sayani A; Doucette S; Iczkovitz S; Terres JAR
Lupus; 2017 Feb; 26(2):119-124. PubMed ID: 27365369
[TBL] [Abstract][Full Text] [Related]
7. Identification of clinical predictors of flare in systemic lupus erythematosus patients: a 24-month prospective cohort study.
Inês L; Duarte C; Silva RS; Teixeira AS; Fonseca FP; da Silva JA
Rheumatology (Oxford); 2014 Jan; 53(1):85-9. PubMed ID: 24067885
[TBL] [Abstract][Full Text] [Related]
8. Clinical and laboratory characteristics and long-term outcome of pediatric systemic lupus erythematosus: a longitudinal study.
Hiraki LT; Benseler SM; Tyrrell PN; Hebert D; Harvey E; Silverman ED
J Pediatr; 2008 Apr; 152(4):550-6. PubMed ID: 18346514
[TBL] [Abstract][Full Text] [Related]
9. The effect of menopause on disease activity in systemic lupus erythematosus.
Urowitz MB; Ibañez D; Jerome D; Gladman DD
J Rheumatol; 2006 Nov; 33(11):2192-8. PubMed ID: 16981295
[TBL] [Abstract][Full Text] [Related]
10. Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE.
Ibañez D; Gladman DD; Urowitz MB
J Rheumatol; 2005 May; 32(5):824-7. PubMed ID: 15868616
[TBL] [Abstract][Full Text] [Related]
11. Predictors of cognitive dysfunction in patients with systemic lupus erythematosus.
McLaurin EY; Holliday SL; Williams P; Brey RL
Neurology; 2005 Jan; 64(2):297-303. PubMed ID: 15668428
[TBL] [Abstract][Full Text] [Related]
12. Systemic lupus erythematosus in a multiethnic US cohort, XXXVII: association of lymphopenia with clinical manifestations, serologic abnormalities, disease activity, and damage accrual.
Vilá LM; Alarcón GS; McGwin G; Bastian HM; Fessler BJ; Reveille JD;
Arthritis Rheum; 2006 Oct; 55(5):799-806. PubMed ID: 17013840
[TBL] [Abstract][Full Text] [Related]
13. Cigarette smoking and cutaneous damage in systemic lupus erythematosus.
Turchin I; Bernatsky S; Clarke AE; St-Pierre Y; Pineau CA
J Rheumatol; 2009 Dec; 36(12):2691-3. PubMed ID: 19884279
[TBL] [Abstract][Full Text] [Related]
14. Infections in newly diagnosed Spanish patients with systemic lupus erythematosus: data from the RELES cohort.
González-Echavarri C; Capdevila O; Espinosa G; Suárez S; Marín-Ballvé A; González-León R; Rodríguez-Carballeira M; Fonseca-Aizpuru E; Pinilla B; Pallarés L; Ruiz-Irastorza G;
Lupus; 2018 Dec; 27(14):2253-2261. PubMed ID: 30451641
[TBL] [Abstract][Full Text] [Related]
15. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus.
Brunner HI; Gladman DD; Ibañez D; Urowitz MD; Silverman ED
Arthritis Rheum; 2008 Feb; 58(2):556-62. PubMed ID: 18240232
[TBL] [Abstract][Full Text] [Related]
16. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXI. Disease activity, damage accrual, and vascular events in pre- and postmenopausal women.
Fernández M; Calvo-Alén J; Alarcón GS; Roseman JM; Bastian HM; Fessler BJ; McGwin G; Vilá LM; Sanchez ML; Reveille JD
Arthritis Rheum; 2005 Jun; 52(6):1655-64. PubMed ID: 15934092
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the relationship between disease activity and damage in patients with systemic lupus erythematosus--a 5-yr prospective study.
Stoll T; Sutcliffe N; Mach J; Klaghofer R; Isenberg DA
Rheumatology (Oxford); 2004 Aug; 43(8):1039-44. PubMed ID: 15161983
[TBL] [Abstract][Full Text] [Related]
18. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort.
Shinjo SK; Bonfá E; Wojdyla D; Borba EF; Ramirez LA; Scherbarth HR; Brenol JC; Chacón-Diaz R; Neira OJ; Berbotto GA; De La Torre IG; Acevedo-Vázquez EM; Massardo L; Barile-Fabris LA; Caeiro F; Silveira LH; Sato EI; Buliubasich S; Alarcón GS; Pons-Estel BA;
Arthritis Rheum; 2010 Mar; 62(3):855-62. PubMed ID: 20131238
[TBL] [Abstract][Full Text] [Related]
19. Summarizing disease features over time: II. Variability measures of SLEDAI-2K.
Ibañez D; Gladman D; Urowitz M
J Rheumatol; 2007 Feb; 34(2):336-40. PubMed ID: 17183620
[TBL] [Abstract][Full Text] [Related]
20. Clinical features and prognosis of late-onset systemic lupus erythematosus: results from the 1000 faces of lupus study.
Lalani S; Pope J; de Leon F; Peschken C;
J Rheumatol; 2010 Jan; 37(1):38-44. PubMed ID: 20008925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
